In an era of increasing environmental consciousness, the pharmaceutical industry finds itself at a critical juncture. With the implementation of the EU's Corporate Sustainability Reporting Directive in January 2024, large pharmaceutical organisations are facing growing pressure to enhance their sustainability reporting practices. Our latest white paper, "Benchmarking Scope 3 Emissions Reporting Across the Pharmaceutical Industry," offers an in-depth exploration of this timely topic. The paper discusses the growing emphasis on addressing Scope 3 emissions and the trend towards more comprehensive reporting and adoption of science-based targets. Here's a glimpse of what you'll discover in our comprehensive analysis: Key Sustainability Frameworks and Initiatives shaping the pharmaceutical sector's approach to sustainability Industry-Wide Challenges and complexities of Scope 3 emissions reporting Comprehensive analysis of Scope 3 emissions data from the top 25 pharmaceutical and biotech org

June 20, 2024 With the climate crisis intensifying and the impending regulatory requirements for environmental reporting, there is a heightened focus on how companies are tackling environmental sustainability challenges across their supply chain operations. Sustainability reporting is becoming mandatory in many regions, and transparent reporting ensures compliance with these regulations. The implementation of global regulations and mandatory sustainability reporting is revolutionising the landscape of global supply chains, fostering a culture of environmental responsibility. By sharing sustainability initiatives and challenges transparently, pharma companies can inspire others, facilitate knowledge-sharing, and foster collaboration within and across industries. Transparent reporting also allows companies to identify gaps, set targets, and track progress, driving continuous improvement in their sustainability practices. This white paper offers a concise summary of key dates and mileston

March 21, 2023 The science is clear: Emissions need to fall 45% by 2030 to avoid the worst climate impacts. Limiting global warming to well below 2 degrees Celsius can avoid further impact on global health, according to the Intergovernmental Panel on Climate Change (IPCC). Healthcare stakeholders must play their part by accelerating the delivery of patient-centric, equitable, net zero health systems. As the latest report by the IPCC shows, this is no longer a challenge for tomorrow: we are already seeing the impacts today with increased incidence of events such as extreme heat, floods, and wildfires across the globe. We need to act urgently and reduce emissions globally to limit further global warming. The pharmaceutical industry has a significant impact on the environment due to the large quantities of energy, water, and raw materials required for drug manufacturing. As a result, there is growing pressure for pharmaceutical companies to embed environmental sustainability into their op